Blogs about Biotechnology, Pharmaceutical and Healthcare

01:26 EDT 1st June 2016 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 57,000+

Tuesday 31st May 2016

At Long Last, New Chemical Safety Regulations

Congress is ready to fix the law meant to keep Americans safe from harmful chemicals.

This Health Care Dividend Aristocrat Will Profit From Old Age - Globally

Sun’s Sales Outlook Disappoints Market

Investors have hammered down shares of Sun Pharma after the world’s fifth-largest generic drug company issued a lower than expected sales forecast for this financial year.

Japan PCSK9 Rivalry Builds As Praluent Edges Closer To Market

Sanofi's Praluent looks set to become the second PCSK9 inhibitor available in Japan following a new recommendation for approval, but can it hold its own against launched rival Repatha? Meanwhile, AstraZeneca’s Brilinta is facing a delay.

Expanded Voluntary Recall on Certain Backroad Country Brand Sunflower Kernel Products

Troyer® Cheese Inc, under advice from its packaging facility concerning, CRANBERRY NUT DELIGHT MIX PREPACK, HONEY ISLAND CRUNCH MIX PREPACKAGED, PRETZELS PEANUT BUTTER PREPACKAGED, WALNUT HALVES/PIECES PREPACKAGED, SUNFLOWER SEEDS R&S PREPACKAGED AND SUNFLOWER SEEDS R&S BULK is recalling a limited number of products that have the potential to be contaminated with Listeria monocytogenes, an organ...

Two Years After Paying $680M, BioMarin Shelves Duchenne Drug

BioMarin Pharmaceutical took a $680 million gamble when it bought Prosensa in 2014 for its experimental Duchenne muscular dystrophy treatment. Drisapersen (Kydrisa) had already failed a Phase 3 trial, but BioMarin bet it could dig through the data and win FDA approval. It lost that bet, and now BioMarin (NASDAQ: BMRN) is pulling the plug […]

Time to Abandon the Best-of-Breed LIS Label; Emergence of Specialized Lab Software Vendors

I have recently concluded that the term "best-of-breed LIS" has ceased to be useful as products like Epic's Beaker approach the functionality of competing LISs. Beaker still lacks a blood bank module which causes customers to seek one from another vendor. Epic has been assisted in its pursuit of BoB...

Believe It Or Not, Computer Science Can Help You Solve Your Problems (Without A Computer)

A new book shows how algorithmic thinking from computer science can solve very human problems

Innocoll's (INNL) CEO Tony Zook on Q1 2016 Results - Earnings Call Transcript

Cell Phones Associated With Dozens Of Holiday Weekend Deaths. But Not From Cancer.

Distractions while operating a motor vehicle lead to 8 deaths and 1,161 injuries in the U.S. every single day.

Icahn Takes Big Stake in Allergan, Endorses Drugmaker's CEO

Billionaire investor Carl Icahn took a stake in Allergan PLC and threw his support behind the drug company’s chief executive, Brent Saunders, in a departure from the activist’s usual playbook.

More effective and less invasive: how breast cancer treatment has evolved since the 1950s

By Nicholas Wilcken, University of Sydney Treating breast cancer with a very high dose of chemotherapy doesn’t improve survival any more than if using a standard dose. A recent Cochrane review has put the final nail in the coffin of decades of research debunking the antiquated idea that, if only we could give a high […] The post More effective and less invasive: how breast cancer treatment...

ME sufferer coming to the end of her step-by-step charity challenge | The Argus, Brighton | 31 May 2016

From The Argus, Brighton | 31 May 2016 | Story by Siobhan Ryan. A TEACHING assistant struck down by a debilitating illness with no known cure is set to finish...

Thomas Ehrlich On Colon Surgery

This piece is written by Thomas Ehrlich. He recently recovered from unexpected colon surgery and shares his experience here.

With One Trial Shelved And Another Failed, StemCells To Shut Down

StemCells (NASDAQ: STEM) has decided to close up shop after its most advanced therapy didn’t do enough in a Phase 2 trial to improve people with spinal cord injuries. The one-time stem cell pioneer will wind down operations with $5.5 million in the bank, as of May 31, it said in a statement this morning. […]

NZ Plans Revamp Of ‘Outdated’ Rules To Attract More Trials

As part of its planned overhaul of the regulatory framework for medicines and medical devices, the New Zealand government says it intends to 'realize New Zealand's potential as a clinical trial destination' by updating the clinical trial regulations in line with international norms, and extending trial oversight to all therapeutic products.

FDA Rejects Teva's Application For Huntington's Drug

The Food and Drug Administration rejected a drug application from Teva Pharmaceutical Industries Ltd., asking for more information on the effects of the drug that treats some symptoms of Huntington’s disease.

Gold Medal, Gold Medal Wondra, and Signature Kitchens Flour Recalled Due to Possible E. coli O121 Contamination

General Mills is collaborating with health officials to investigate an ongoing, multistate outbreak of E. coli O121 that may be potentially linked to Gold Medal flour, Wondra flour, and Signature Kitchens flour (sold in Safeway, Albertsons, Jewel, Shaws, Vons, United, Randalls, and Acme). Out of an abundance of caution, a voluntary recall is being made.

Maxim likes ContraVir merger with Ciclofilin

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group analyst Jason Kolbert. The mechanism of action of Ciclofilin’s antiviral asset, CPI-431-32, should be complementary to ContraVir’s CMX157 by inhibiting distinct critical steps in th...

The Biosimilars Forum: Biosimilar Education Relies On "Pure Science"

The Biosimilars Forum recently launched its educational initiative known as the “Partnership for Biosimilar Education and Access.” Throughout the development of this initiative, it became clear to the Forum membership that physicians have specific educational needs that extend far beyond policy.

BioMarin to Stop Developing Kyndrisa

BioMarin Pharmaceutical Inc. will abandon development of an experimental treatment for Duchenne muscular dystrophy and three other related products.

Intercept's Pricing Of Ocaliva Anticipates Outcomes Data

With OCA approved for primary biliary cholangitis, Intercept anticipates a potentially slow ramp of sales, but has priced product at $69,350 a year based on need in second-line treatment and in anticipation of survival benefit data.

Teva Remains Focused On Tardive Dyskinesia After Huntington’s Stumble

FDA's complete response letter for deutetrabenazine for treatment of chorea associated Huntington disease does not request additional clinical trials, and Teva said a filing timeline for tardive dyskinesia remains unchanged.

Medtronic's (MDT) CEO Omar Ishrak on Q4 2016 Results - Earnings Call Transcript

'Brotox': It's Time For Men To Come Out Of The Closet

Every guy needs to admit this one honest truth: Feeling that you’re getting old sucks, no matter what your age. We all look in the mirror every morning and judge ourselves on how we look. The numbers also don’t lie. According to the American Society of Plastic Surgeons, over 400,000 U.S. [...]

Quick Search